Williamson et al.
Oct 10, 2021
This study investigates the therapeutic efficacy of human monoclonal antibodies (mAbs) against Andes virus (ANDV), the causative agent of hantavirus cardiopulmonary syndrome (HCPS).
This study investigates the therapeutic efficacy of human monoclonal antibodies (mAbs) against Andes virus (ANDV), the causative agent of hantavirus cardiopulmonary syndrome (HCPS), in a Syrian hamster model. The goal was to evaluate mAb cocktail treatment at different stages of infection.
Key findings:
Early-Stage Treatment (5+9 days post-infection): Hamsters treated with a cocktail of mAbs (MIB22 + JL16) showed 100% survival, significantly reduced viral RNA in lung tissue, and improved clinical outcomes compared to the control group.
Late-Stage Treatment (8+10 days post-infection): Treatment at later stages showed partial efficacy, with 50% survival in the treated group, though viral RNA loads were not significantly different from the control group.
Overall Conclusion: The mAb cocktail provided complete protection when administered early and partial protection when administered at later stages of infection. This highlights the potential for using these mAbs as postexposure countermeasures for ANDV infection, even in later disease stages, though further optimization of treatment schedules is needed.